You are here
CELDARA MEDICAL, LLC
UEI: MMVKQXZUBMQ7
# of Employees: 15
HUBZone Owned: No
Socially and Economically Disadvantaged: No
Woman Owned: No
Award Charts
Award Listing
-
A human monoclonal antibody therapy for treatment of hantavirus cardiopulmonary syndrome
Amount: $1,000,000.00PROJECT SUMMARY Rodent-borne viral outbreaks are increasing in both frequency and impact. As weather patterns evolve, rodent populations are affected and may multiply in areas where increased contact ...
STTRPhase II2023Department of Health and Human Services National Institutes of Health -
Kv2.1-Targeted First in Class Neuroprotective Therapeutic for Acute Ischemic Stroke
Amount: $231,974.00Project Summary Acute ischemic stroke (AIS) impacts 795,000 Americans per year, leaving 90% of patients with chronic disability. Prevalent cases of AIS in the US were estimated at 6.7M in 2017, transl ...
SBIRPhase I2023Department of Health and Human Services National Institutes of Health -
Development of CM-CS1 CAR Treg to Treat Amyotrophic Lateral Sclerosis (ALS)
Amount: $466,950.00SUMMARY Amyotrophic lateral sclerosis (ALS) patients develop fatal paralysis as a result of progressive motor neuron loss in the brain and spinal cord. There are more than 5,000 new cases of ALS per y ...
SBIRPhase I2023Department of Health and Human Services National Institutes of Health -
Anti-hIAPP for the preservation of pancreatic function in Type 2 Diabetes
Amount: $999,432.00Project Summary According to the American Diabetes Association, Type 2 diabetes mellitus (T2D) affects at least 30 million Americans and is a major unmet public health concern with an annual cost in t ...
SBIRPhase II2023Department of Health and Human Services National Institutes of Health -
Preclinical development of an important, broad-spectrum antibody for pandemic influenza
Amount: $999,635.00Health and human services (HHS) and the Biomedical Advanced Research and Development Authority (BARDA) have suggested a severe pandemic influenza outbreak is the greatest current threat to national an ...
SBIRPhase II2023Department of Health and Human Services National Institutes of Health -
Development of a broad spectrum antimicrobial to combat chronic lung infection
Amount: $300,590.00Project Summary Bacterial resistance has reached alarming levels in the US and other parts of the world in the past decade. The increase in bacterial infection with antimicrobial resistant (AMR) patho ...
SBIRPhase I2022Department of Health and Human Services National Institutes of Health -
Development of CM-IAV1 for Treatment of High-risk Pandemic Influenzas
Amount: $300,000.00Project Summary Health and human services (HHS) and the Biomedical Advanced Research and Development Authority (BARDA) have suggested a severe pandemic influenza outbreak is the greatest current threa ...
SBIRPhase I2022Department of Health and Human Services National Institutes of Health -
CAR T platform to treat solid tumors
Amount: $368,052.00SUMMARY Cancer is one of the leading causes of death worldwide. Over the years, several treatment approaches have been developed. However, their effectiveness is severely limited by the heterogeneity ...
SBIRPhase I2022Department of Health and Human Services National Institutes of Health -
Anti-hIAPP for the preservation of pancreatic function in Type 2 Diabetes
Amount: $267,818.00Project Summary According to the American Diabetes Association, Type 2 diabetes mellitus (T2D) affects at least 30 million Americans and is a major unmet public health concern with an annual cost in t ...
SBIRPhase I2022Department of Health and Human Services National Institutes of Health -
Preclinical development of CM-CX1 for the treatment of ovarian clear cell and renal cell carcinomas
Amount: $1,482,122.00PROJECT SUMMARY Cancer is one of the leading causes of death worldwide. Over the years, a number of conventional cytotoxic approaches for neoplastic diseases has been developed. However, due to their ...
SBIRPhase II2022Department of Health and Human Services National Institutes of Health